Our mission is to help improve outcomes and reduce complications in as many patients as possible.
The Snapshot Suit includes two powerful imaging devices: SnapshotNIR, a near-infrared tissue oxygenation imaging device initially cleared by the FDA and Health Canada in 2017, and with CE Marking in 2025, and SnapshotGLO, a bacterial autofluorescence imaging device that received FDA 510(k) clearance in 2025.
Together, the Snapshot Suite enhances clinicians’ ability to detect, direct, and protect—promoting consistency of treatment, improving outcomes, and advancing the standard of care for patients worldwide.
Learn more: www.kentimaging.com/
Learn about SnapshotNIR: www.kentimaging.com/snapshotnir
Learn more about SnapshotGLO: www.kentimaging.com/snapshotglo